Go Pro
NASDAQ:FBLG

FibroBiologics Q2 2026 Earnings Report

FibroBiologics logo
$1.35 -0.09 (-6.25%)
Closing price 08/24/2026 04:00 PM Eastern
Extended Trading
$1.34 -0.02 (-1.11%)
As of 05:05 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

FibroBiologics EPS Results

Actual EPS
-$0.66
Consensus EPS
-$0.93
Beat/Miss
Beat by +$0.27
One Year Ago EPS
N/A

FibroBiologics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

FibroBiologics Announcement Details

Quarter
Q2 2026
Time
Before Market Opens
Conference Call Date
Friday, July 31, 2026
Conference Call Time
7:00AM ET

Upcoming Earnings

FibroBiologics' Q3 2026 earnings is estimated for Friday, October 30, 2026, based on past reporting schedules, with a conference call scheduled at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

FibroBiologics Earnings Headlines

FibroBiologics Appoints Leigh Steinberg to Board of Directors
Trump's New Dollar
Porter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. dollar reset - and most Americans don't know it's happening. The last time America underwent a monetary shift like this, under Nixon in the 1970s, it minted an average of 1,300 new millionaires a day for over half a century. Stansberry has released a new documentary naming the assets he believes are positioned to surge as a result.tc pixel
See More FibroBiologics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like FibroBiologics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on FibroBiologics and other key companies, straight to your email.

About FibroBiologics

FibroBiologics (NASDAQ:FBLG), Inc. operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. It holds 150+ U.S. and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer. FibroBiologics, Inc. was incorporated in 2021 and is based in Houston, Texas.

View FibroBiologics Profile